What are the current permanent and temporary deferral criteria for voluntary blood donors, with recent references?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Blood Donor Deferral Criteria

Blood donor deferral criteria should follow evidence-based, risk-stratified approaches that balance donor and recipient safety, with temporary deferrals accounting for approximately 85-97% of all deferrals and permanent deferrals reserved for conditions posing ongoing transmission risk or donor harm.

Permanent Deferral Criteria

Infectious Disease-Related

  • HTLV-I/II seropositivity: Donors with repeatedly reactive HTLV-I enzyme immunoassay results confirmed by supplemental testing are permanently deferred 1
  • HIV infection: Confirmed HIV-positive donors are permanently excluded 2
  • Hepatitis C: Active HCV infection constitutes permanent deferral 3
  • Hepatitis B surface antigen positive: Note that hepatitis B surface antibody alone is NOT a contraindication 4

Behavioral Risk Factors

The landscape has evolved significantly from blanket lifetime bans to time-based deferrals:

  • Men who have sex with men (MSM): Shifted from lifetime ban to 12-month deferral as of 2015, with further evolution toward individual risk assessment models since 2020 2, 5
  • Intravenous drug users: Permanent deferral remains standard 2
  • Recipients of animal organs or tissues: Permanent deferral 2

Medical Conditions

  • Malignancy: May be acceptable if deemed cured with oncology clearance; otherwise permanent deferral 4
  • Chronic conditions posing ongoing risk: Evaluated on case-by-case basis 6

Temporary Deferral Criteria

Hematologic

  • Low hemoglobin/hematocrit: The single most common deferral reason (21.6-45.9% of all deferrals) 7, 8, 9, 10
    • These donors show lower return rates, particularly first-time and female donors
    • Requires iron supplementation and dietary counseling before re-donation

Cardiovascular

  • Hypertension: Second most common deferral (11.4-22.9%) 7
    • Defer until blood pressure <130/80 mmHg 4
  • Hypotension: Accounts for 4.5-8.8% of deferrals 7, 10

Infectious/Illness-Related

  • Recent illness/common cold: 15.8-21.9% of deferrals 7, 9
  • Recent antibiotic use: 9.3-9.8% of deferrals 9, 10
  • History of jaundice: 9-18.6% of deferrals pending evaluation 7
  • Tuberculosis exposure: Requires PPD testing and clearance 4
  • Travel to endemic areas: Variable deferral periods based on disease risk 2

Medication-Related

  • Recent medication use: 9.3% of deferrals 10
  • Nephrotoxic agents: Should be avoided long-term in donors 4

Donor-Specific Factors

  • Obesity (BMI >35 kg/m²): Relative contraindication, especially with comorbidities 4
  • Recent donation: Standard inter-donation intervals apply
  • Jehovah's Witnesses/transfusion refusal: Relative contraindication 4

Key Epidemiologic Patterns

Deferral Rates by Donor Type

The evidence demonstrates clear stratification:

  • First-time donors: 32.19% deferral rate 8
  • Repeat donors: 18.18% deferral rate 8
  • Regular donors: 8.98% deferral rate 8

This represents a strong effect size (η²=0.24), indicating donor experience significantly reduces deferral risk.

Gender Disparities

  • Female donors: 30.68% deferral rate (OR=2.70 vs males) 8
  • Male donors: 14.08% deferral rate 8
  • Primary driver is anemia in females, requiring targeted interventions

Geographic Variation

  • Overall deferral rates: Range 11.6-27.4% globally 6, 8, 9
  • North American centers: Tend to be less restrictive 6
  • European centers: More regulatory restrictions 6
  • Inverse correlation with Human Development Index (r=-0.67) 8

Critical Practice Points

Indeterminate Results

For donors with repeatedly reactive screening tests but unconfirmed results:

  • Defer after two separate donations with same result 1
  • Do NOT tell donors they are infected 1
  • Provide counseling that results may be false-positive
  • Refer for physician evaluation, especially if elevated ALT 3

Notification Requirements

  • Written notification required for all deferred donors 3
  • Face-to-face interview or sealed letter 3
  • For deceased organ donors, notify donor's physician 3

Return Rates After Temporary Deferral

The evidence shows concerning patterns:

  • New donors: 0-40% return rate depending on deferral reason 10
  • Regular donors: 37.5-100% return rate 10
  • Low Hb/Hct deferrals: Lowest return rates across all categories 10

This highlights the critical need for donor education, reminder systems, and follow-up interventions to maintain blood supply adequacy.

Recent Evolution (2020-Present)

The most significant change has been implementation of individual risk assessment models for HIV risk mitigation, replacing time-based categorical deferrals with personalized risk evaluation 5. This represents a shift from population-based to behavior-based screening, though implementation challenges remain regarding standardization and training.

Common Pitfalls to Avoid

  1. Over-reliance on categorical deferrals: Current evidence supports risk-stratified approaches rather than blanket bans 2, 6

  2. Inadequate follow-up of temporarily deferred donors: 86.2% of deferrals are temporary and potentially modifiable 8, yet return rates remain suboptimal without active intervention

  3. Failure to address anemia systematically: As the leading deferral cause, this requires population-level interventions including dietary fortification and screening programs 7

  4. Inconsistent application of criteria: Wide geographic variation suggests reliance on local experience rather than evidence 6, necessitating standardization efforts

The evidence base remains limited for many specific conditions 6, 11, with most criteria based on regulatory requirements or institutional experience rather than published data, highlighting the need for ongoing research and evidence generation.

References

Guideline

evaluation of the potential living kidney donor.

American Journal of Kidney Diseases, 2007

Research

Review of blood donor deferral with emphasis on donor and patient safety.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2023

Research

Blood donor deferral patterns in Iran: six-year national analysis (2016-2021).

Blood transfusion = Trasfusione del sangue, 2026

Research

Donor Screening and Deferral.

Clinics in laboratory medicine, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.